Table 1.

Major checkpoint inhibitors in clinical development for metastatic melanoma

Drug	Other Names	Target	Antibody Class	Producer	Clinical Stage Completed in Melanoma
Ipilimumab	MDX010	CTLA-4	IgG1 human	Bristol-Myers Squibb	FDA approved 2011
Nivolumab	MDX-1106, BMS-936558, ONO-4538	PD-1	IgG4 fully human	Bristol-Myers Squibb	FDA approved 2014
Pembrolizumab	MK-3475, lambrolizumab	PD-1	IgG4 humanized	Merck	FDA approved 2014
Pidilizumab	CT-011	PD-1	IgG1 humanized	Curetech	Phase II
Atezolizumab	MPDL3280A	PD-L1	IgG1 engineered fully human	Roche	Phase II
BMS-935559	MDX-1105	PD-L1	IgG4 fully human	Bristol-Myers Squibb	Phase I
Durvalamab	MEDI4736	PD-L1	IgG1 engineered fully human	MedImmune/AstraZeneca	Phase I/II
IMP321	None	LAG3	LAG3-Ig fusion	Prima	Phase 1 ongoing